Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo-controlled study.

Sivalingam S, Wasehuus VS, Rotbain Curovic V, Blond MB, Hansen TW, Persson F, Rossing P

Diabetes, obesity & metabolism18 Sept 2023Cited by 31 (Europe PMC)

PMID37722966DOI10.1111/dom.15287PepBankPUB-37722966

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and albuminuria on empagliflozin, adding semaglutide gave no significant additional change in UACR versus placebo.
In plain wordsIn adults with type 2 diabetes and albuminuria already on empagliflozin, adding semaglutide did not lower urine albumin more than placebo.
Peptide
Semaglutide
Outcome
No significant changeChange in urinary albumin-creatinine ratio
Study
n = 60
Comparator
Placebo (on top of empagliflozin)
Analysis
Primary
Outcome group
Kidney function · Kidney and urinary
Studied dose
1 mg once weekly · 26 weeksAs given in this study (human).
Measurements
UACR difference
−22%
semaglutide vs placebo
Source sentences
Summary
Addition of semaglutide to empagliflozin provided no additional change in UACR from randomization to end-of-treatment. The mean (95% confidence interval) difference in UACR was -22 (-44; 10)% (P = 0.15) between treatment groups.
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized, placebo-controlled, double-blind, parallel study including 60 individuals with T2D and albuminuria.
Summary · context
All participants initiated open-label empagliflozin 25 mg once daily, on top of renin-angiotensin system inhibition, in a run-in period of 26 weeks.
Summary · context
Subsequently, participants were randomized to semaglutide or placebo 1 mg once weekly for 26 weeks.
Report a problemFND-3772296601
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and albuminuria on empagliflozin, semaglutide did not change measured GFR.
In plain wordsIn adults with type 2 diabetes and albuminuria already on empagliflozin, adding semaglutide did not change kidney filtration.
Peptide
Semaglutide
Outcome
No significant changeMeasured glomerular filtration rate
Study
n = 60
Comparator
Placebo (on top of empagliflozin)
Analysis
Secondary
Outcome group
Kidney function · Kidney and urinary
Studied dose
1 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Neither GFR, 24-hour blood pressure, body weight, nor plasma renin activity was changed with semaglutide.
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized, placebo-controlled, double-blind, parallel study including 60 individuals with T2D and albuminuria.
Summary · context
All participants initiated open-label empagliflozin 25 mg once daily, on top of renin-angiotensin system inhibition, in a run-in period of 26 weeks.
Summary · context
Subsequently, participants were randomized to semaglutide or placebo 1 mg once weekly for 26 weeks.
Report a problemFND-3772296602
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and albuminuria on empagliflozin, semaglutide did not change 24-hour blood pressure.
In plain wordsIn adults with type 2 diabetes and albuminuria already on empagliflozin, adding semaglutide did not change 24-hour blood pressure.
Peptide
Semaglutide
Outcome
No significant change24-hour blood pressure
Study
n = 60
Comparator
Placebo (on top of empagliflozin)
Analysis
Secondary
Outcome group
Blood pressure · Cardiovascular
Studied dose
1 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Neither GFR, 24-hour blood pressure, body weight, nor plasma renin activity was changed with semaglutide.
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized, placebo-controlled, double-blind, parallel study including 60 individuals with T2D and albuminuria.
Summary · context
All participants initiated open-label empagliflozin 25 mg once daily, on top of renin-angiotensin system inhibition, in a run-in period of 26 weeks.
Summary · context
Subsequently, participants were randomized to semaglutide or placebo 1 mg once weekly for 26 weeks.
Report a problemFND-3772296603
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and albuminuria on empagliflozin, semaglutide did not change body weight.
In plain wordsIn adults with type 2 diabetes and albuminuria already on empagliflozin, adding semaglutide did not change body weight.
Peptide
Semaglutide
Outcome
No significant changeBody weight
Study
n = 60
Comparator
Placebo (on top of empagliflozin)
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
1 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Neither GFR, 24-hour blood pressure, body weight, nor plasma renin activity was changed with semaglutide.
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized, placebo-controlled, double-blind, parallel study including 60 individuals with T2D and albuminuria.
Summary · context
All participants initiated open-label empagliflozin 25 mg once daily, on top of renin-angiotensin system inhibition, in a run-in period of 26 weeks.
Summary · context
Subsequently, participants were randomized to semaglutide or placebo 1 mg once weekly for 26 weeks.
Report a problemFND-3772296604
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and albuminuria on empagliflozin, semaglutide did not change plasma renin activity.
In plain wordsIn adults with type 2 diabetes and albuminuria already on empagliflozin, adding semaglutide did not change plasma renin activity.
Peptide
Semaglutide
Outcome
No significant changePlasma renin activity
Study
n = 60
Comparator
Placebo (on top of empagliflozin)
Analysis
Secondary
Outcome group
Kidney function · Endocrine and hormones
Studied dose
1 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Neither GFR, 24-hour blood pressure, body weight, nor plasma renin activity was changed with semaglutide.
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized, placebo-controlled, double-blind, parallel study including 60 individuals with T2D and albuminuria.
Summary · context
All participants initiated open-label empagliflozin 25 mg once daily, on top of renin-angiotensin system inhibition, in a run-in period of 26 weeks.
Summary · context
Subsequently, participants were randomized to semaglutide or placebo 1 mg once weekly for 26 weeks.
Report a problemFND-3772296605
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and albuminuria on empagliflozin, semaglutide reduced HbA1c by 8 mmol/mol compared with placebo.
In plain wordsIn adults with type 2 diabetes and albuminuria already on empagliflozin, adding semaglutide lowered HbA1c more than placebo.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change
Study
n = 60
Comparator
Placebo (on top of empagliflozin)
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1 mg once weekly · 26 weeksAs given in this study (human).
Measurements
HbA1c difference
−8 mmol/mol
semaglutide vs placebo
Source sentences
Summary
HbA1c (-8 [-13; -3] mmol/mol; P = 0.003)
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized, placebo-controlled, double-blind, parallel study including 60 individuals with T2D and albuminuria.
Summary · context
All participants initiated open-label empagliflozin 25 mg once daily, on top of renin-angiotensin system inhibition, in a run-in period of 26 weeks.
Summary · context
Subsequently, participants were randomized to semaglutide or placebo 1 mg once weekly for 26 weeks.
Report a problemFND-3772296606
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and albuminuria on empagliflozin, semaglutide reduced plasma aldosterone by 30 pmol/L compared with placebo.
In plain wordsIn adults with type 2 diabetes and albuminuria already on empagliflozin, adding semaglutide lowered the hormone aldosterone more than placebo.
Peptide
Semaglutide
Outcome
DecreasePlasma aldosterone change
Study
n = 60
Comparator
Placebo (on top of empagliflozin)
Analysis
Secondary
Outcome group
Blood pressure · Endocrine and hormones
Studied dose
1 mg once weekly · 26 weeksAs given in this study (human).
Measurements
Aldosterone difference
−30 pmol/L
semaglutide vs placebo
Source sentences
Summary
plasma aldosterone (-30 [-50; -3] pmol/L; P = 0.035)
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized, placebo-controlled, double-blind, parallel study including 60 individuals with T2D and albuminuria.
Summary · context
All participants initiated open-label empagliflozin 25 mg once daily, on top of renin-angiotensin system inhibition, in a run-in period of 26 weeks.
Summary · context
Subsequently, participants were randomized to semaglutide or placebo 1 mg once weekly for 26 weeks.
Report a problemFND-3772296607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo-controlled study.

Summary

Results from this study7

Version history

Subjects

Publication types

MeSH terms

Keywords